P2RY12 and coronary artery disorder: Patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI) are generally prescribed dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 inhibitor (P2Y12i), for 6-12 months to prevent recurrent atherothrombotic events (1, 2).